跳至正文
OpenAgentSkill
浏览已开放 · 目录记录日期 2026-11-21 · 自动更新和账户服务暂时关闭。
设计与 UI

pipeline-vaccines

Vaccine pipeline analysis: immunogenicity and seroconversion studies, lot-consistency trials, healthy-population efficacy designs, and age-cohort bridging, with the ACIP gate built into the value path across the med universe.

agentii-ai · 已有静态检查记录

安装与使用

运行命令前先阅读来源与依赖说明。复制命令不会自动安装或执行。

npx skills add agentii-ai/agentii-investment-intelligence --skill pipeline-vaccines

技能说明


name: pipeline-vaccines description: "Vaccine pipeline analysis: immunogenicity and seroconversion studies, lot-consistency trials, healthy-population efficacy designs, and age-cohort bridging, with the ACIP gate built into the value path across the med universe." sectors: [med.medicines_biotech, med.medical_devices] multi_ticker_semantics: single_target temporal_scope: default_quarters: 8 max_quarters: 20 description: "Long-horizon pipeline window default 8 quarters; up to 20 for multi-season bridging and booster cycles." allowed_tools:

  • get_company_drugs
  • search_universe_drugs
  • search_acip_events
  • get_acip_event
  • search_clinical_trials
  • get_clinical_trial
  • search_fda_approvals
  • search_companies
  • search_knowledge_entries retrieval_scope: structured_only min_tool_diversity: 3 parameter_free: false

Methodology inspired by publicly taught vaccine development frameworks; all text is an original paraphrase.

Defaults

ParameterDefault ValueRationale
asset_scopeall disclosed vaccine assetsFull-pipeline enumeration first
evidence_lensimmunogenicity + efficacyCorrelate studies distinguished from efficacy trials
acip_gatetrueACIP path modeled as part of pipeline value
cohort_lenstrueAge-cohort bridging tracked per asset
value_framerisk-adjustedModeled value = unadjusted peak x POS, both shown

Preflight

Run canonical pre-flight per contracts/preflight.md. Propagate X-Agentii-Trace per contracts/x-agentii-trace-header.md. Confirm ticker resolution via search_companies before asset queries.

Triggers

  • "Analyze [ticker]'s vaccine pipeline."
  • "What seroconversion or immunogenicity studies support [vaccine]?"
  • "Where are [ticker]'s vaccines in the efficacy ladder?"
  • "Which lot-consistency trials are pending for [ticker]?"
  • "What age-cohort bridging studies does [ticker] have planned?"
  • "Does [ticker]'s vaccine have an ACIP path?"
  • "Risk-adjust [ticker]'s vaccine pipeline."
  • "What is the next catalyst for each of [ticker]'s vaccine assets?"
  • "How do healthy-population efficacy designs change the evidence bar?"
  • "Map [ticker]'s vaccines by antigen, cohort, and phase."
  • "Which vaccine assets could reach a BLA in the next two years?"
  • "What does [ticker]'s pipeline say about its seasonal strategy?"

Production Grounding

  • Vaccine evidence ladder: immunogenicity/seroconversion studies (correlates, not efficacy) → efficacy trials in healthy populations (large N, safety-first) → lot-consistency trials (immunogenicity equivalence across three manufacturing lots — a licensure gate) → age-cohort bridging for pediatric and elderly label expansion.
  • Healthy-population design: the efficacy bar is safety-first; endpoints prevent infection or disease; power comes from large N, and placebo arms shrink post-licensure (non-inferiority and bridging designs follow).
  • Lot consistency is a regulatory milestone, not a formality: without it, licensure stalls regardless of efficacy data.
  • The ACIP gate is part of pipeline value: a Phase III vaccine without a plausible ACIP path carries an unmodeled commercial step.
  • Booster cycles and variant updates re-open the market; cohort bridging extends the label beyond the pivotal population.
  • Grounding detail lives in references/knowledge-frameworks.md.

Data Source Priority

  1. get_company_drugs / search_universe_drugs — vaccine asset inventory.
  2. search_clinical_trials / get_clinical_trial — study design type, cohorts, status-diff, enrollment.
  3. search_acip_events / get_acip_event — the gate path per vaccine; search_fda_approvals for BLA history.
  4. Knowledge layer: search_knowledge_entries for framework grounding.

Methodology

Retrieval Scope

structured_only

Retrieval Strategy

  1. Pull vaccine assets (get_company_drugs), cross-check the universe (search_universe_drugs).
  2. Enrich per asset with trial records (search_clinical_trials) — design type, cohorts, status.
  3. Map the ACIP path per asset (search_acip_events / get_acip_event).
  4. Layer BLA and approval history (search_fda_approvals).
  5. Size each asset (peak x POS); ground in knowledge entries.

Temporal Scope

See frontmatter temporal_scope block. Seasonal and bridging cycles span years; history may reach back 8-12 quarters.

Tool Allowlist

See frontmatter allowed_tools.

Protocol

  1. Asset enumeration
  2. Evidence-ladder mapping (immunogenicity → efficacy → lot consistency → bridging)
  3. ACIP-path assessment
  4. Cohort and booster overlay
  5. Risk-adjusted synthesis

Modes

  • Phase scan (default): all vaccine assets by stage with next catalyst and ACIP path.
  • Cohort bridge: age-cohort expansions, booster cycles, and label breadth.
  • Competitor map: antigen and indication overlap with class-read.

Tool Fallbacks

FailureFallback
get_company_drugs emptysearch_universe_drugs by company or indication; annotate coverage_gap
No trial rowsMark design type undisclosed; do not guess efficacy vs immunogenicity
No ACIP rowsFlag the gate path unmodeled; never assume approval = availability
Knowledge tools emptyProceed with structured data only

Output File

{ticker}/{YYYY-MM-DD_HHMM}_pipeline-vaccines_{affix}.md

Output Structure

  1. Executive Summary — pipeline stance in 2-3 sentences
  2. Asset Table — stage, design type, cohorts, next catalyst, ACIP path
  3. Evidence Ladder — immunogenicity vs efficacy vs lot-consistency status per asset
  4. Cohort & Booster Map — bridging studies, label breadth, seasonal strategy
  5. Risk-Adjusted Sizing — peak x POS with the two-gate path made explicit
  6. Coverage Gaps — missing records, undisclosed design, degraded modes

Error Handling

ErrorFallback
Study design unknownMark "undisclosed"; do not guess
Efficacy vs co
阅读完整来源 ↗